美沙拉嗪与双歧杆菌四联活菌联合治疗溃疡性结肠炎的效果分析

Effect analysis of mesalazine combined with Bifidobacterium tetravaccine in the treatment of ulcerative colitis

目的 探讨美沙拉嗪联合双歧杆菌四联活菌对溃疡性结肠炎的临床治疗效果。方法 96例溃疡性结肠炎患者,采用随机分组的方式分为实验组和对照组,每组48例。对照组实施美沙拉嗪治疗,实验组在对照组基础上联合双歧杆菌四联活菌治疗。对比两组患者的治疗效果、疾病复发情况以及治疗前后炎症指标[降钙素原(PCT)、肿瘤坏死因子-α(TNF-α)、高迁移率族蛋白B1(HMGB1)]。结果 实验组患者的治疗总有效率95.83%明显高于对照组的60.42%,差异具有统计学意义(P<0.05)。实验组患者的疾病复发率14.58%明显低于对照组的45.83%,差异具有统计学意义(P<0.05)。治疗前,两组患者的PCT、TNF-α、HMGB1对比,差异无统计学意义(P>0.05);治疗后,实验组患者的PCT(0.45±0.14)ng/ml、TNF-α(38.47±3.23)pg/ml、HMGB1(12.32±1.46)ng/ml均低于对照组的(0.82±0.23)ng/ml、(52.57±4.34)pg/ml、(22.53±1.55)ng/ml,差异有统计学意义(P<0.05)。结论 美沙拉嗪联合双歧杆菌四联活菌对溃疡性结肠炎的临床治疗效果显著,可以有效降低疾病的复发率及炎症指标水平,值得在临床治疗中广泛运用。

Objective To discuss the clinical effect of mesalazine combined with Bifidobacterium tetravaccine in the treatment of ulcerative colitis.Methods A total of 96 patients with ulcerative colitis were randomly divided into an experimental group and a control group,with 48 cases in each group.The control group was treated with mesalazine,and the experimental group was treated with Bifidobacterium tetravaccine on the basis of the control group.Both groups were compared in terms of therapeutic effect,disease recurrence and inflammatory indicators[procalcitonin(PCT),tumor necrosis factor-α(TNF-α),high mobility group protein B1(HMGB1)]before and after treatment.Results The total effective rate of 95.83%in the experimental group was significantly higher than that of 60.42%in the control group,and the difference was statistically significant(P<0.05).The recurrence rate of 14.58%in the experimental group was significantly lower than that of 45.83%in the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in PCT,TNF-αand HMGB1 between the two groups(P>0.05).After treatment,the experimental group had PCT of(0.45±0.14)ng/ml,TNF-αof(38.47±3.23)pg/ml and HMGB1 of(12.32±1.46)ng/ml,which were lower than those of(0.82±0.23)ng/ml,(52.57±4.34)pg/ml and(22.53±1.55)ng/ml in the control group,and the differences were statistically significant(P<0.05).Conclusion Mesalazine combined with Bifidobacterium tetravaccine is effective in the clinical treatment of ulcerative colitis.It can effectively reduce the recurrence of the disease and lower the levels of inflammatory indicators.It is worthy to be widely used in clinical treatment.